Xencor, Inc. (XNCR) fundamentals score
Xencor is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases, who have unmet medical needs. It uses its protein engineering capabilities to design new technologies and XmAb drug candidates with improved properties and multi-target mechanisms of action.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 3.6 out of 10, Weak long-term fundamentals
- Growth: 5.0/10
- Profitability: 1.0/10
- Financial health: 4.2/10
- Earnings quality: 6.0/10
- Valuation: 2.3/10
Scores are calculated from Xencor, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10